Raltegravir combined with Kaletra associated with good preservation of bone density over 96 weeks

This article is more than 10 years old. Click here for more recent articles on this topic

A two-drug antiretroviral combination comprising raltegravir and ritonavir-boosted lopinavir has only a modest impact on bone mineral density, a study presented to the International AIDS Society conference (IAS 2011) in Rome shows.

The raltegravir (Isentress) and lopinavir/ritonavir (Kaletra) combination had the same potency as a more traditional antiretroviral regimen – FTC/tenofovir (Truvada) and Kaletra. However, the tenofovir-containing regimen was associated with decreases in both total bone density and density of bone in the lower spine.

“Over 96 weeks of therapy, total bone density decreased to a greater extent in the tenofovir/FTC plus lopinavir/ritonavir group than in the raltegravir plus lopinavir/ritonavir group,” comment the investigators.

Glossary

bone mineral density (BMD)

The higher your bone mineral content, the denser your bones are. And the denser your bones, the stronger they are and the less likely they are to break. A bone density test uses X-rays to measure how many grams of calcium and other bone minerals are packed into a segment of bone. The bones that are most commonly tested are in the spine, hip and sometimes the forearm. 

metabolism

The physical and chemical reactions that produce energy for the body. Metabolism also refers to the breakdown of drugs or other substances within the body, which may occur during digestion or elimination.

integrase inhibitors (INI, INSTI)

A class of antiretroviral drugs. Integrase strand transfer inhibitors (INSTIs) block integrase, which is an HIV enzyme that the virus uses to insert its genetic material into a cell that it has infected. Blocking integrase prevents HIV from replicating.

dual energy x-ray absorptiometry scan (DXA or DEXA)

A test that uses low-dose x-rays to measure bone mineral density, including calcium content, in a section of bone. They are used to detect osteoporosis and predict the risk of bone fracture. 

boosting agent

Booster drugs are used to ‘boost’ the effects of protease inhibitors and some other antiretrovirals. Adding a small dose of a booster drug to an antiretroviral makes the liver break down the primary drug more slowly, which means that it stays in the body for longer times or at higher levels. Without the boosting agent, the prescribed dose of the primary drug would be ineffective.

It is now well recognised that reduced bone density is a complication of HIV infection. Bone loss has been associated with duration of HIV infection, and with immune reconstitution on treatment, and treatment with specific anti-HIV drugs may also affect the bone metabolism.

Tenofovir – a widely used drug in first-line antiretroviral therapy – has been especially associated with a reduction in bone density.

There is a fear that long-term disturbances in bone metabolism could increase the risk of fractures for an ageing HIV population, and the comparison of regimens with and without tenofovir is beginning to shed more light on extent to which tenofovir might affect bone mineral density, and in what circumstances.

Investigators from the PROGRESS study therefore compared changes in bone mineral density after two years of HIV treatment in patients treated with the integrase inhibitor raltegravir to those seen in individuals taking Truvada-based therapy.

Reductions in bone mineral density have been seen in patients treated with Kaletra, but the impact of raltegravir therapy on the bones is unknown.

Bone mineral density was assessed using DEXA scans at baseline and again after 96 weeks.

A total of 205 patients were randomised in the open-label study. Approximately 75% were men, 19% were black and the average age was 40 years. All were starting HIV therapy for the first time.

Baseline factors associated with lower bone mineral density were black race (p = 0.004), a viral load over 100,000 copies/ml (p = 0.006), a lower body mass index (p < 0.001), and lower levels of limb fat (p = 0.026).

After 48 and 96 weeks of treatment similar proportions of patients in both treatment arms had an undetectable viral load, and gains in CD4 cell count were also comparable between the two regimens.

After 96 weeks of therapy, total bone mineral density was essentially unchanged from baseline among the raltegravir-treated patients.

However, there was a reduction of approximately 2% among the patients taking tenofovir, a significant difference (p < 0. 05).

In addition, only modest reductions in bone density in the spine were recorded among the raltegravir-treated patients, but a reduction of approximately 5% was observed in those taking tenofovir (p < 0.05).

A 5% loss in bone density at week 96 was seen in fewer than 5% of patients taking raltegravir, compared to approximately 20% of individuals in the tenofovir arm (p = 0.003).

The investigators believe that this finding could be of clinical significance, noting “the decreases observed in the lopinavir/ritonavir plus tenofovir/FTC group are similar in magnitude to the bone mineral density losses observed during the first two years of menopause”.

Statistical analysis confirmed that patients taking raltegravir were less likely to experience loss of total bone density than individuals treated with tenofovir (odds ratio [OR] = 0.14; 95% CI, 0.04-0.55, p = 0.005).

Baseline characteristics associated the preservation of bone density during the two years of the study included younger age (under 40 vs over 40, p = 0.018), a higher CD4 cell count (over 200 vs under 200 cells/mm3, p = 0.011), and higher body mass index (p  =0.02).

“The minimal effect of raltegravir, in combination with lopinavir/ritonavir, on bone mineral density with antiretroviral initiation warrants confirmation through further study,” the researchers conclude.

References

Qaquish RB et al. Bone mineral density (BMD) analysis in antiretroviral (ART)-naïve subjects taking lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) for 96 weeks in the PROGRESS study. Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Rome, abstract TULBPE021, 2011.

View abstract TULBPE021 on the conference website